Funding Fuels AI-Enabled Personalization, Commercial Expansion, and Partnerships With Leading Employers and Payors

WellTheory, the leading whole-person care platform for autoimmune disease, today announced it has raised $14 million in Series A funding led by General Catalyst with participation from new and existing investors, including 7wire Ventures, Ingeborg Investments, Accel, Box Group, Leaps by Bayer, and Up2 Opportunity Fund. With $26.2M million in total capital, this new funding will fuel WellTheory’s commercial growth, accelerate AI development, and expand programs that meet growing demand from employers and payors.

Autoimmune disease is one of the fastest-growing and most expensive categories in healthcare, doubling over the last three decades and affecting more than 50 million Americans living with conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. The autoimmune category now represents a growing market valued at over 160 billion dollars, and has become a top spend category for employers and payors. With specialty drug costs climbing, payors and employers are urgently seeking solutions that both improve patient outcomes and reduce spend.

“WellTheory is building the future of autoimmune care with a model that’s uniquely designed for today’s workforce,” said Ellen Rudolph, CEO and Co-Founder of WellTheory. “Employers are facing rising costs, while employees wait years for answers on their own health — a frustrating journey I experienced firsthand. By combining high-touch care with AI-enabled personalization, we’re addressing both parties, delivering a better quality of life for patients and measurable cost reductions for employers and payors.”

"WellTheory is addressing the impact of autoimmune disease by recognizing the important role that diet and lifestyle can play in supporting patients,” said Candace Richardson, partner at General Catalyst, who is joining the company’s board. “The platform is demonstrating how this kind of support can be delivered at scale, and this is just the beginning. It is expanding to integrate medical treatment and medication management, creating a more comprehensive model designed to improve patient experiences and strengthen system sustainability.”

WellTheory will use the funding to deepen partnerships with employers and payors, expand care programs targeting the fastest-growing cost centers in healthcare, and invest in AI-enabled personalization. Together, these efforts will allow the company to deliver whole-person autoimmune care at greater scale while reducing costs for patients and partners alike.

“Employers and payers are urgently seeking solutions that improve outcomes while reducing costs. WellTheory’s AI-powered, whole-person model is proving it can do both,” said Tiffany Yu, Principal at 7wire Ventures. “We are impressed by the company’s ability to deliver meaningful savings for its partners today while also setting a new standard for a personalized, consumer-first experience.”

In just 18 months on the commercial market, WellTheory has secured partnerships with Fortune 100 and 500 employers and high-growth companies including Maven Clinic, Fortune Brands Innovations, and Dayforce, as well as payors such as Sentara Health Plans and one of the top national payors. These partners are already seeing measurable impact: independent claims analyses show WellTheory reduces ER visits, imaging, hospitalizations, and biologics utilization while saving thousands of dollars per patient annually.

In the past year alone, WellTheory has seen 10× year-over-year member growth and 5× revenue growth — underscoring both the scale of the need and the effectiveness of its model. This momentum builds on the company’s recent launch of its AI-powered platform, which introduced proprietary tools Care Hub and Care Scribe, now fully deployed across its care operations.

About WellTheory:

WellTheory is a virtual care platform reversing the autoimmune epidemic by filling the gaps left behind in traditional healthcare. WellTheory offers a research-backed proprietary program that addresses the root cause of autoimmunity and treats the whole person with the aim to reduce symptoms, improve quality of life, and lower costs. WellTheory’s platform centers around evidence-based, high-touch care led by an interdisciplinary team of autoimmune experts, including licensed registered dietitians and board-certified health coaches. It’s an anti-symptom-masking model that goes beyond the pill, built by autoimmune patients and validated by decades of clinical research.

About General Catalyst:

General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond. With offices in San Francisco, New York City, Boston, Berlin, Bangalore, and London, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Applied Intuition, Commure, Glean, Guild, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

For more: www.generalcatalyst.com, @generalcatalyst

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014695952/en/